Nephrotic Syndrome - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Nephrotic Syndrome - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Nephrotic Syndrome - Pipeline Review, H1 2016', provides an overview of the Nephrotic Syndrome pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Nephrotic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome
- The report reviews pipeline therapeutics for Nephrotic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Nephrotic Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Nephrotic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Nephrotic Syndrome


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Nephrotic Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nephrotic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Nephrotic Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Nephrotic Syndrome - Overview 7
Pipeline Products for Nephrotic Syndrome - Comparative Analysis 8
Nephrotic Syndrome - Therapeutics under Development by Companies 9
Nephrotic Syndrome - Therapeutics under Investigation by Universities/Institutes 10
Nephrotic Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Nephrotic Syndrome - Products under Development by Companies 14
Nephrotic Syndrome - Products under Investigation by Universities/Institutes 15
Nephrotic Syndrome - Companies Involved in Therapeutics Development 16
Asahi Kasei Pharma Corp. 16
Bristol-Myers Squibb Company 17
Orbis Biosciences, Inc. 18
Retrophin Inc. 19
Nephrotic Syndrome - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
abatacept - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cosyntropin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
mizoribine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
prednisone - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Recombinant Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
SP-20104 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Nephrotic Syndrome - Recent Pipeline Updates 38
Nephrotic Syndrome - Dormant Projects 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Number of Products under Development for Nephrotic Syndrome, H1 2016 7
Number of Products under Development for Nephrotic Syndrome - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp., H1 2016 16
Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2016 17
Nephrotic Syndrome - Pipeline by Orbis Biosciences, Inc., H1 2016 18
Nephrotic Syndrome - Pipeline by Retrophin Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Nephrotic Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 38
Nephrotic Syndrome - Dormant Projects, H1 2016 42